Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC trimmed its position in Inari Medical, Inc. (NASDAQ:NARI) by 2.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,560 shares of the company’s stock after selling 327 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Inari Medical were worth $642,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its position in shares of Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after acquiring an additional 435 shares in the last quarter. GAMMA Investing LLC raised its holdings in Inari Medical by 67.2% during the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after purchasing an additional 473 shares in the last quarter. KBC Group NV lifted its position in shares of Inari Medical by 39.0% during the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after buying an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after buying an additional 522 shares in the last quarter. Finally, Covestor Ltd boosted its holdings in shares of Inari Medical by 63.5% in the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after buying an additional 926 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Trading Up 2.1 %

Shares of NARI stock opened at $56.75 on Tuesday. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $67.10. The business’s 50 day moving average is $49.03 and its two-hundred day moving average is $47.99. The company has a market capitalization of $3.32 billion, a P/E ratio of -42.04 and a beta of 0.97.

Insider Activity at Inari Medical

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the sale, the chief executive officer now owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. The trade was a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the transaction, the director now owns 601,233 shares in the company, valued at $27,067,509.66. The trade was a 6.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 143,000 shares of company stock worth $7,022,400 in the last three months. Insiders own 10.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NARI. Leerink Partners initiated coverage on shares of Inari Medical in a research note on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 price target on the stock. Canaccord Genuity Group lifted their target price on Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Robert W. Baird upped their target price on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, October 29th. Stifel Nicolaus assumed coverage on Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target on the stock. Finally, Piper Sandler boosted their price objective on Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a research note on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $58.89.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.